Novartis Showcases Scemblix® Phase III ASC4FIRST Study Data in New CML Patients at ASCO and EHA

Novartis is set to present data from over 60 abstracts at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2024 Hybrid Congress. Among the highlights are the primary results from the ASC4FIRST pivotal Phase III study of Scemblix® (asciminib) compared to standard tyrosine kinase inhibitors (imatinib, nilotinib, dasatinib, and bosutinib) in newly diagnosed patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP). These results will be shared at the ASCO official Press Program and the EHA Plenary Session.

Jeff Legos, Executive Vice President and Global Head of Oncology at Novartis, stated, "Despite progress, people with CML continue to struggle to find treatment that is both efficacious and tolerable for them at diagnosis and beyond. We look forward to sharing the primary analysis from the pivotal Phase III ASC4FIRST trial, which builds on our over 20-year legacy to transform care for people diagnosed with CML."

Additionally, Novartis will present new data from the Kisqali®* NATALEE trial, which focuses on the efficacy endpoints for patients with node-negative stage II and III HR+/HER2- early breast cancer. There will also be updates on their radioligand therapy (RLT) portfolio, showcasing overall platform leadership and ongoing expansion in research infrastructure and supply capabilities.

At the ASCO Annual Meeting, Novartis will also address health equity issues at their booth with a unique virtual reality experience called More Than Just Words. This experience allows meeting attendees to immerse themselves in scenarios inspired by real-life microaggressions that Black patients face due to bias in care. Participants will explore resources co-created with leading multidisciplinary experts to help foster productive, nonbiased conversations about breast cancer risk, diagnosis, and care.

Novartis, a leading innovative medicines company, is committed to reimagining medicine to improve and extend people's lives. Their treatments reach over 250 million people globally, empowering patients, healthcare professionals, and societies in the face of serious diseases.

This year's presentations at the ASCO and EHA conferences highlight Novartis' ongoing efforts in oncology, particularly in chronic myeloid leukemia and early breast cancer. The results from these studies underscore their dedication to advancing cancer treatment and addressing health disparities in care.